# Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)

Study · id `cardio:ct-nct03768427` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03768427](<https://clinicaltrials.gov/study/NCT03768427>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03768427

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 454 participants.

## Technical summary

Registry record NCT03768427. Randomized; double masking; primary purpose treatment. Start 2019-05-27 (actual); primary completion 2021-03-17 (actual). Results posted on 2023-02-08.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 454 participants (enrolled count; ClinicalTrials.gov record NCT03768427, source copy `cardio:ctgov-nct03768427-2024-05-16`, retrieved 2026-10-31)
- Started: 2019-05-27 (actual) (ClinicalTrials.gov record NCT03768427, source copy `cardio:ctgov-nct03768427-2024-05-16`, retrieved 2026-10-31)
- Primary completion: 2021-03-17 (actual) (ClinicalTrials.gov record NCT03768427, source copy `cardio:ctgov-nct03768427-2024-05-16`, retrieved 2026-10-31)
- Completion: 2021-04-01 (actual) (ClinicalTrials.gov record NCT03768427, source copy `cardio:ctgov-nct03768427-2024-05-16`, retrieved 2026-10-31)
- Results first posted: 2023-02-08 (ClinicalTrials.gov record NCT03768427, source copy `cardio:ctgov-nct03768427-2024-05-16`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT03768427, source copy `cardio:ctgov-nct03768427-2024-05-16`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03768427-2024-05-16`, retrieved 2026-10-31)

## The registry's words

- Brief title: Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)
- Condition: Hypercholesterolemia
- Intervention (Combination product): EZ 10 mg/Ator 10 mg
- Intervention (Combination product): EZ 10 mg/Ator 20 mg
- Intervention (Drug): Atorvastatin
- Intervention (Drug): Placebo for FDC EZ/Ator
- Intervention (Drug): Placebo for atorvastatin
- Lead sponsor: Organon and Co
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)
- Registry lists this organization as the lead sponsor: Organon and Co (`cardio:org-organon-and-co`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and Tolerability of Ezetimibe/Atorvastatin Fixed-dose Combination Versus Atorvastatin Monotherapy in Hypercholesterolemia: A Phase III, Randomized, Active-controlled Study in Chinese Patients (`cardio:pubmed-36182594`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: LDL-C Goal Attainment with Fixed-Dose Ezetimibe and Atorvastatin Versus High-Dose Atorvastatin in Chinese Patients: Subgroup Analysis of a Randomized Trial (`cardio:pubmed-41553712`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 54b8cebe0c77865fb360b4a208c7dd67cb35fc35e970aee48eaa25016fddcf28
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
